BioSpace News Archive

CBD Naturals® and NanoSphere™ Technologies have announced a strategic partnership designed to develop more nano-products.

IQVIA Holdings Inc. announced the pricing of an underwritten, secondary public offering of 12,000,000 shares of its common stock by certain of its existing stockholders

Samsung Bioepis Co., Ltd. and Biogen today announced pooled analysis results of three anti-tumor necrosis factor (anti-TNF) biosimilars – BENEPALI™ (SB4, etanercept biosimilar), FLIXABI™ (SB2, infliximab biosimilar), and IMRALDI™ (SB5, adalimumab biosimilar).

Investment Accelerates naviHealth’s Growing Market Position in Post-Acute Care Management

About 1 in 2 colorectal cancers in Canada are diagnosed after they have spread to lymph nodes or other parts of the body, even though most provinces and territories have screening programs designed to catch the disease early or before it starts, according to a new report released today by the Canadian Cancer Society (CCS).

Newron Pharmaceuticals S.p.A. announces that the STARS clinical study (Sarizotan Treatment of Apneas in Rett Syndrome) in patients with Rett syndrome is expected to complete enrollment in H2 2018.

Maxar Technologies announced that Maxar President and CEO Howard Lance will be holding one-on-one and group meetings with investors, as well as participating in a panel discussion on “The Evolution of Commercial Space” at the Melius Research Industrial Tech & Aerospace Forum

Elbit Systems Ltd. announced that it’s subsidiary, Beyeonics Surgical Ltd. (“Beyeonics”), concluded a first round of funding raising a $11.5 million investment from leading investment groups including an international corporation.

Vizient, Inc. announced its support for the Stretching Entity Resources for Vulnerable (SERV) Communities Act.

“234" asks the public to help change lung cancer statistics